4.7 Article

Small-molecule costimulatory blockade: organic dye inhibitors of the CD40-CD154 interaction

Journal

JOURNAL OF MOLECULAR MEDICINE-JMM
Volume 87, Issue 11, Pages 1133-1143

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00109-009-0519-3

Keywords

Azo dyes; CD40L; Direct red 80; Immune suppression; Protein-protein interaction; THP-1 cells

Funding

  1. Diabetes Research Institute Foundation
  2. Future Leadership Foundation, Inc.
  3. Rowland and Sylvia Schaefer Family Foundation

Ask authors/readers for more resources

Costimulatory blockade is one of the most promising therapeutic targets in autoimmune diseases as well as in transplant recipients, and inhibition of the cluster of differentiation (CD)40-CD154 interaction, which is required for T cell activation and development of an effective immune response, is particularly promising in islet transplant recipients. Here, we report the ability of several small-molecule organic dyes to concentration dependently inhibit this interaction with IC50 values in the low-micromolar range. They were found to be considerably more active in inhibiting this interaction than the tumor necrosis factor (TNF)-R1-TNF-alpha or B cell-activating factor (BAFF)-R-BAFF interaction, which are members of the same family. They specifically inhibited CD154-induced cell responses in human B cells as well as in THP-1 myeloid cells, which can serve as surrogate dendritic cells, at concentrations well below their cytotoxic concentrations determined in the same cells. Flow cytometry experiments confirmed their ability to inhibit the CD154-induced, but not the Staphylococcus aureus Cowan I- or phorbol 12-myristate 13-acetate-induced increase in the surface expression of CD54, CD40, and major histocompatibility complex class II. Accordingly, these compounds can be useful not only for experimental investigations involving the inhibition of the CD40-CD154 costimulatory interaction but can also provide important structure-activity relationship information and can serve as the starting point of a targeted drug discovery program.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available